Product
Febuxostat
Aliases
Febuxostat-Reference product, febuxostat tablets + placebo of HR091506 tablets, Febuxostat-Test product, Uloric
Name
Febuxostat
INN Name
febuxostat
FDA Approved
Yes
10 clinical trials
23 organizations
8 indications
2 documents
Indication
Healthy SubjectsIndication
GoutIndication
Gout with Hyperuricemia in AdultsIndication
Chronic Kidney DiseaseIndication
Non-Alcoholic SteatohepatitisIndication
HyperuricemiaIndication
Nonalcoholic Fatty Liver DiseaseClinical trial
A Bioequivalence Study of a Randomized, Open-label, Single Dose, Two-way Crossover Design With Two-period, Two-treatment and Two-sequence of Febuxostat 80 mg Tablets Relative to Feburic® in Healthy Thai Volunteers Under Fasting ConditionStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout PatientsStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Study on Efficacy and Safety of HR091506 Tablets in Treatment of Gout With Hyperuricemia in AdultsStatus: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With GoutStatus: Completed, Estimated PCD: 2023-06-14
Clinical trial
CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. FebuxostatStatus: Completed, Estimated PCD: 2021-02-01
Clinical trial
Comparative Study Evaluating the Outcome of Febuxostat Versus Vitamin E in Hyperuricemia Patients With Non-alcoholic Steatohepatitis Without CirrhosisStatus: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Study on Efficacy and Safety of HR091506 Tablets in Treatment of Gout With Hyperuricemia in AdultsStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Allopurinol Versus Febuxostat: A New Approach for Management of Hepatic Steatosis in Metabolic-Associated Fatty Liver DiseaseStatus: Completed, Estimated PCD: 2023-01-28
Clinical trial
A Novel Assay for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites: Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion in APRT Deficient PatientsStatus: Completed, Estimated PCD: 2015-05-01
Clinical trial
Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic SyndromeStatus: Completed, Estimated PCD: 2015-03-01
Organization
Aphena Pharma Solutions - Tennessee, LLCOrganization
MSN LABORATORIES PRIVATE LIMITEDOrganization
Rebel Distributors Corp.Document
DailyMed Label: FebuxostatOrganization
NuCare Pharmaceuticals,Inc.Organization
Macleods Pharmaceuticals LimitedDocument
DailyMed Label: ULORICOrganization
Takeda Pharmaceuticals America, Inc.Organization
NorthStar RxLLCOrganization
Alembic Pharmaceuticals LimitedOrganization
American Health PackagingOrganization
Ascend Laboratories, LLCOrganization
Alembic Pharmaceuticals Inc.Organization
Aurobindo Pharma LimitedOrganization
Tris Pharma IncOrganization
Golden State Medical Supply, Inc.Organization
Viona Pharmaceuticals IncOrganization
Hikma Pharmaceuticals USA Inc.Organization
Solco Healthcare US LLCOrganization
Novadoz Pharmaceuticals LLCOrganization
Major PharmaceuticalsOrganization
Sun Pharmaceutical Industries, Inc.Organization
Lannett Company, Inc.Organization
Aphena Pharma Solutions - Tennessee, LLC Organization
Zydus Lifesciences Limited